Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Abstract

Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols.